Baerere af cystisk fibrose har øget risiko for asthma. Osterbroundersøgelsen

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Baerere af cystisk fibrose har øget risiko for asthma. Osterbroundersøgelsen. / Dahl, Morten; Tybjærg-Hansen, Anne; Lange, P; Nordestgaard, B G.

I: Ugeskrift for Laeger, Bind 161, Nr. 32, 09.08.1999, s. 4507-9.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Dahl, M, Tybjærg-Hansen, A, Lange, P & Nordestgaard, BG 1999, 'Baerere af cystisk fibrose har øget risiko for asthma. Osterbroundersøgelsen', Ugeskrift for Laeger, bind 161, nr. 32, s. 4507-9.

APA

Dahl, M., Tybjærg-Hansen, A., Lange, P., & Nordestgaard, B. G. (1999). Baerere af cystisk fibrose har øget risiko for asthma. Osterbroundersøgelsen. Ugeskrift for Laeger, 161(32), 4507-9.

Vancouver

Dahl M, Tybjærg-Hansen A, Lange P, Nordestgaard BG. Baerere af cystisk fibrose har øget risiko for asthma. Osterbroundersøgelsen. Ugeskrift for Laeger. 1999 aug. 9;161(32):4507-9.

Author

Dahl, Morten ; Tybjærg-Hansen, Anne ; Lange, P ; Nordestgaard, B G. / Baerere af cystisk fibrose har øget risiko for asthma. Osterbroundersøgelsen. I: Ugeskrift for Laeger. 1999 ; Bind 161, Nr. 32. s. 4507-9.

Bibtex

@article{de64557aba9f42408c0f828045e52cff,
title = "Baerere af cystisk fibrose har {\o}get risiko for asthma. Osterbrounders{\o}gelsen",
abstract = "We tested the hypothesis that individuals heterozygous for the common cystic fibrosis delta F508 mutation are at risk of obstructive pulmonary disease. We studied a cross-sectional sample from the general population of Copenhagen, aged 20 years and older. We performed spirometry to measure FEV1 and FVC, and genotyped blood samples from 9141 individuals. We identified 250 carriers of the delta F508 mutation (2.7%; 95% CI: 2.5%-3.1%). Nine precent of carriers reported having asthma compared with 6% of non-carriers (chi 2: p = 0.04). Furthermore, among individuals with airway obstruction, the percentage of predicted FEV1 and FVC were significantly lower in participants heterozygous for delta F508 than in non-carriers (49% vs. 58%, p = 0.004 and 70% vs. 82%, p <0.001, respectively). Cystic fibrosis delta F508 heterozygosity may be over-represented among people with asthma and seems to be associated with decreased pulmonary function in people with airway obstruction who also have asthma.",
keywords = "Adult, Asthma, Cross-Sectional Studies, Cystic Fibrosis, Denmark, Female, Forced Expiratory Volume, Genetic Predisposition to Disease, Heterozygote Detection, Humans, Male, Vital Capacity",
author = "Morten Dahl and Anne Tybj{\ae}rg-Hansen and P Lange and Nordestgaard, {B G}",
year = "1999",
month = aug,
day = "9",
language = "Dansk",
volume = "161",
pages = "4507--9",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "32",

}

RIS

TY - JOUR

T1 - Baerere af cystisk fibrose har øget risiko for asthma. Osterbroundersøgelsen

AU - Dahl, Morten

AU - Tybjærg-Hansen, Anne

AU - Lange, P

AU - Nordestgaard, B G

PY - 1999/8/9

Y1 - 1999/8/9

N2 - We tested the hypothesis that individuals heterozygous for the common cystic fibrosis delta F508 mutation are at risk of obstructive pulmonary disease. We studied a cross-sectional sample from the general population of Copenhagen, aged 20 years and older. We performed spirometry to measure FEV1 and FVC, and genotyped blood samples from 9141 individuals. We identified 250 carriers of the delta F508 mutation (2.7%; 95% CI: 2.5%-3.1%). Nine precent of carriers reported having asthma compared with 6% of non-carriers (chi 2: p = 0.04). Furthermore, among individuals with airway obstruction, the percentage of predicted FEV1 and FVC were significantly lower in participants heterozygous for delta F508 than in non-carriers (49% vs. 58%, p = 0.004 and 70% vs. 82%, p <0.001, respectively). Cystic fibrosis delta F508 heterozygosity may be over-represented among people with asthma and seems to be associated with decreased pulmonary function in people with airway obstruction who also have asthma.

AB - We tested the hypothesis that individuals heterozygous for the common cystic fibrosis delta F508 mutation are at risk of obstructive pulmonary disease. We studied a cross-sectional sample from the general population of Copenhagen, aged 20 years and older. We performed spirometry to measure FEV1 and FVC, and genotyped blood samples from 9141 individuals. We identified 250 carriers of the delta F508 mutation (2.7%; 95% CI: 2.5%-3.1%). Nine precent of carriers reported having asthma compared with 6% of non-carriers (chi 2: p = 0.04). Furthermore, among individuals with airway obstruction, the percentage of predicted FEV1 and FVC were significantly lower in participants heterozygous for delta F508 than in non-carriers (49% vs. 58%, p = 0.004 and 70% vs. 82%, p <0.001, respectively). Cystic fibrosis delta F508 heterozygosity may be over-represented among people with asthma and seems to be associated with decreased pulmonary function in people with airway obstruction who also have asthma.

KW - Adult

KW - Asthma

KW - Cross-Sectional Studies

KW - Cystic Fibrosis

KW - Denmark

KW - Female

KW - Forced Expiratory Volume

KW - Genetic Predisposition to Disease

KW - Heterozygote Detection

KW - Humans

KW - Male

KW - Vital Capacity

M3 - Tidsskriftartikel

C2 - 10477965

VL - 161

SP - 4507

EP - 4509

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 32

ER -

ID: 45524394